|
JPH10503179A
(ja)
|
1994-06-24 |
1998-03-24 |
イミュネックス・コーポレーション |
放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
|
|
IL112834A
(en)
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
|
US6020004A
(en)
|
1997-04-17 |
2000-02-01 |
Amgen Inc. |
Biodegradable microparticles for the sustained delivery of therapeutic drugs
|
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
US6432449B1
(en)
|
1998-05-18 |
2002-08-13 |
Amgen Inc. |
Biodegradable sustained-release alginate gels
|
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
|
US6451346B1
(en)
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
|
KR20100031769A
(ko)
*
|
2000-12-28 |
2010-03-24 |
알투스 파마슈티컬스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
|
US8821086B2
(en)
*
|
2006-12-22 |
2014-09-02 |
Tennine Corporation |
Method and apparatus for controlled-fracture machining
|
|
WO2008109871A2
(en)
*
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
BRPI0810551A2
(pt)
*
|
2007-04-13 |
2019-09-03 |
Novartis Ag |
moléculas e métodos para modulação da pró-proteína convertase subtilisina/quexina tipo 9 (pcsk9)
|
|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
AU2009238550B2
(en)
*
|
2008-04-23 |
2014-11-27 |
Amgen Inc. |
Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof
|
|
KR100985090B1
(ko)
*
|
2008-05-23 |
2010-10-04 |
한국과학기술연구원 |
크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
|
|
WO2011028938A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
IN2012DN03824A
(enExample)
*
|
2009-10-30 |
2015-08-28 |
Merck Sharp & Dohme |
|
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
MX385311B
(es)
*
|
2011-01-28 |
2025-03-18 |
Sanofi Biotechnology |
Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
|
|
US20140004122A1
(en)
*
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
ITPN20110039A1
(it)
*
|
2011-05-24 |
2012-11-25 |
Keyline S P A |
Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
EA039663B1
(ru)
*
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
*
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
MX352457B
(es)
*
|
2012-05-17 |
2017-11-24 |
Cyon Therapeutics Inc |
Metodos y usos para inhibidores de proproteina convertasa subtilisina kexina 9 (pcsk9).
|
|
RU2015101113A
(ru)
*
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
ES2834113T3
(es)
*
|
2013-03-15 |
2021-06-16 |
H Lundbeck As |
Purificación de anticuerpos y monitorización de la pureza
|
|
CA2906508A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
KR20160024906A
(ko)
*
|
2013-06-07 |
2016-03-07 |
사노피 바이오테크놀로지 |
Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
|
|
CA2916259C
(en)
*
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
US20150004174A1
(en)
*
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
ES2914978T3
(es)
*
|
2013-10-11 |
2022-06-20 |
Sanofi Biotechnology |
Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
|
|
EP3068803B1
(en)
*
|
2013-11-12 |
2021-01-20 |
Sanofi Biotechnology |
Dosing regimens for use with pcsk9 inhibitors
|
|
US8883157B1
(en)
*
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
*
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
*
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
EP3104879A2
(en)
*
|
2014-02-14 |
2016-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
|
JP2017512457A
(ja)
*
|
2014-02-21 |
2017-05-25 |
メディミューン，エルエルシー |
抗ｐｃｓｋ９〜ｇｌｐ−１融合物および使用方法
|
|
US20150283236A1
(en)
*
|
2014-03-17 |
2015-10-08 |
Marie Baccara-Dinet |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
|
PL3119810T3
(pl)
*
|
2014-03-17 |
2024-07-15 |
Sanofi Biotechnology |
Sposoby obniżania ryzyka sercowo-naczyniowego
|
|
EP3169710A1
(en)
*
|
2014-07-14 |
2017-05-24 |
Amgen Inc. |
Crystalline antibody formulations
|
|
WO2016010924A1
(en)
*
|
2014-07-14 |
2016-01-21 |
Amgen Inc. |
Crystalline antibody formulations
|
|
CN107206068A
(zh)
*
|
2014-07-16 |
2017-09-26 |
赛诺菲生物技术公司 |
用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
|
|
WO2016046684A1
(en)
*
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
EP3834864A1
(en)
*
|
2016-04-08 |
2021-06-16 |
Amgen Inc. |
Drug delivery device, method of manufacture, and method of use
|
|
WO2017186928A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
MX2019003727A
(es)
*
|
2016-09-29 |
2019-08-05 |
Amgen Inc |
Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
|
|
WO2018067987A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
JOP20190112A1
(ar)
*
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
US20190031774A1
(en)
*
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
AU2018350992A1
(en)
*
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
CA3106115A1
(en)
*
|
2018-07-08 |
2020-01-16 |
Specifica Inc. |
Antibody libraries with maximized antibody developability characteristics
|